Tuesday, September 16, 2008

CryoLife Expands Distribution of Hemostase MPH(R) to France through Laboratoire Gamida

CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it has begun distribution in France, through Laboratoire Gamida, of Hemostase MPH for use in general, cardiac and vascular surgery.
CryoLife began distributing Hemostase MPH in the U.S., the United Kingdom and Germany in the second quarter of 2008. Distribution in other markets outside the U.S. is planned for later in 2008 and in 2009.
Hemostase MPH is developed using Microporous Polysaccharide Hemospheres technology (MPH(R)), which yields a plant-based powder engineered to rapidly dehydrate blood, enhancing clotting on contact. When used as directed, this hemostatic or antibleeding agent facilitates the formation of a resilient, natural clot within just a few minutes. Hemostase MPH received CE Mark approval in 2003 and FDA pre-market approval in September 2006.
Available in a convenient ready-to-use applicator, Hemostase MPH, unlike many hemostatic agents, does not require additional operating room preparation or special storage conditions. In addition, pre-clinical evaluations have shown that Hemostase MPH does not promote infection and absorbs within 24-48 hours of application at the wound site, compared to other surgical hemostats which can take 3-8 weeks or more to fully break down.
"As a complement to CryoLife's BioGlue(R) product line, Hemostase MPH gives surgeons the ability to quickly control active surgical bleeding, and we are pleased to begin offering this product in France," stated Steven G. Anderson, president and chief executive officer. "We will showcase Hemostase MPH at the European Association of Cardiothoracic Surgeons meeting in Lisbon, Portugal later this week."

TraumaCure Receives Health Canada Licensure

TraumaCure Inc. today announced that Health Canada has issued a medical device license for WoundStat™, a ground-breaking hemostatic agent for control of bleeding in high-pressure arterial wounds. The availability of WoundStat in Canada enables military, emergency medical services, law enforcement services, rescue services, and other first responders to stop arterial bleeding within seconds and stabilize an injured person, giving the time needed to seek advanced medical help and save lives.
TraumaCure also announced an exclusive distributor agreement with Canadian Tactical and Operational Medical Solutions Inc. (CTOMS), the highly regarded provider of Combat Casualty Care training and supplier of high quality medical equipment, to make WoundStat immediately available throughout Canada. CTOMS is based in Edmonton, Alberta